



August 22, 2011

To whom it may concern

NanoCarrier Co., Ltd
Ichiro Nakatomi, Ph.D., President & CEO
(Code No.; 4571 Tokyo Stock Exchange Mothers)
Contact: Takuma Nakatsuka, CFO and Director
Administration, Head of President's Office
TEL: +81-3-3548-0217

**Substance patent of the Paclitaxel-micelle (NK105)
was allowed in South Korea**

A patent application regarding a polymeric micelle preparation encapsulating a sparingly water soluble anticancer agent such as Paclitaxel was allowed in South Korea.

The patent application is co-owned by NanoCarrier and Nippon Kayaku, and due to the allowance, we will obtain the substance patent of the polymeric micelle preparation that is expected to reduce a side effect of the anticancer agent in Japan, United States, Europe, Canada, Russia, China, Australia and South Korea.

Title of the invention: MICELLAR PREPARATION CONTAINING SPARINGLY
WATER-SOLUBLE ANTICANCER AGENT AND NOVEL BLOCK
COPOLYMER

Patent application number: 1 0 – 2 0 0 5 – 7 0 1 7 2 4 5

Patentee: Nippon Kayaku Co.,Ltd. and NanoCarrier Co., Ltd.

The substance patent covers the Paclitaxel-micelle formulation (NK105) that Nippon Kayaku Co. Ltd. proceeds clinical trials for gastric and breast cancer with a phase III study expect to start from early next year.